Spinnaker Tip #4 - Save time with "Quick Entry" on changes

Spinnaker tracks changes that people make to your database. At the most basic level we track who made the change, what day/time they made it, and the before and after snapshots of each data point changed.

We know this can be a pain and we are here to help not hinder. So look out for the "Quick Entry" option.  When you have multiple changes on a form AND they are all for the same reason, click the Quick Entry link to shrink that list down to just a single entry explaining the changes for all the data points.

Congratulations TARGET

Congratulations to all the team on TARGET which opened for enrolments last week and has already enrolled 23 patients across Australia and New Zealand. It’s a privilege working with so many dedicated people. The offline conditions and hold ups on this trial challenged us all but we got there in the end, on budget and all still talking to each other. Kudos to the project manager.   

TARGET stands for "The Augmented versus Routine approach to Giving Energy Trial". TARGET is a 4,000 patient, multicentre, double-blinded, randomised, controlled, parallel-group, phase III clinical trial designed primarily to determine if augmentation of calorie delivery improves 90 day survival in mechanically ventilated patients.  Don’t hold your breathe waiting for the results, they are 4 years away. 

Tip #2: DIY locations

Some software makes it hard to add locations. With Spinnaker the Project Manager can easily add locations and control access to the software. Part of the "Manage" section in Spinnaker.

Case study: CAMERA2: A novel way of treating MRSA

I’d like to recognise the work done by the CAMERA team in getting the CAMERA Trial off the ground and flying. It's 6 months since the study started taking enrolments. Recruitment is on target, hospitals in Singapore and Israel have recently joined the multiple sites across Australia.

The CAMERA Trial - Combination Antibiotic therapy for Methicillin Resistant Staphylococcus Aureus - is a multi-centre RCT to determine if 7 days of intravenous β-lactam in combination with standard therapy will lead to better complication-free survival 90-days after randomisation, compared to standard therapy alone in adult patients with methicillin-resistant S. aureus (MRSA) bloodstream infection.

We are fortunate to work with people making a difference to our future and support Josh, Steve and the CAMERA team with our Spinnaker software. We have written a case study on the trial which you can read here. 

The case study will become part of a suite of trials coming to our new information rich Spinnaker website later this year.

Hope you enjoy the read.

Audrey 

Download the case study